Show items per page
Elements: 6
Page 1 on 1
 TitleAuthors / EditorsDate
add to browser selection
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Finckh, Axel; Ciurea, A.; Brulhart, L.; Moller, B.; ... Gabay, Cem 2010
add to browser selection
Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98 Martinelli, Giovanni; Schmitz, Shu-Fang Hsu; Utiger, Urs; Cerny, Thomas; ... Ghielmini, Michele 2010
add to browser selection
Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab Hristea, Dan; Hadaya, Karine; Marangon, Nicola Danièle Armando; Buehler, Leo Hans; ... Martin, Pierre-Yves 2007
add to browser selection
Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles Cirstoiu, Adriana; Bossy-Nobs, L.; Buchegger, Franz; Gurny, Robert; Delie Salmon, Florence 2007
add to browser selection
Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients Berney, Thierry; Delis, Spiros; Kato, Tomoaki; Nishida, Seigo; ... Tzakis, Andreas G 2002
add to browser selection
Rituximab with interleukin-2 after autologous bone marrow transplantation for acute lymphocytic leukemia in second remission Ozsahin, Ayse Hulya; Fluss, Joel Victor; Mclin, Valérie Anne; Wacker, Pierre; ... Helg, Claudine 2002